Bristol Myers Squibb Company $BMY Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System trimmed its stake in Bristol Myers Squibb Company (NYSE:BMY) by 1.4% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 1,744,698 shares of the biopharmaceutical company’s stock after selling 24,291 shares during the quarter. New York State Teachers Retirement System owned approximately 0.09% of Bristol Myers Squibb worth $105,816,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of BMY. waypoint wealth counsel acquired a new stake in Bristol Myers Squibb in the fourth quarter worth about $1,194,000. Life Cycle Investment Partners Ltd bought a new position in Bristol Myers Squibb in the 4th quarter valued at about $34,406,000. Axxcess Wealth Management LLC increased its stake in Bristol Myers Squibb by 27.4% during the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock valued at $5,322,000 after buying an additional 21,196 shares during the period. Daytona Street Capital LLC bought a new stake in shares of Bristol Myers Squibb during the 4th quarter worth about $1,362,000. Finally, Pensionfund Sabic acquired a new stake in shares of Bristol Myers Squibb in the 4th quarter worth approximately $1,845,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

BMY opened at $58.05 on Friday. The firm has a market capitalization of $118.54 billion, a P/E ratio of 16.31, a PEG ratio of 0.16 and a beta of 0.23. The stock has a fifty day moving average of $56.92 and a 200-day moving average of $57.48. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The business had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts forecast that Bristol Myers Squibb Company will post 6.32 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.3%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 70.79%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on BMY. Guggenheim reiterated a “buy” rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Cantor Fitzgerald upped their target price on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 8th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.